Zydus has launched Olaparib, a PARP inhibitor, under the brand name IBYRA in India. The drug will target specific genetic mutations prevalent in certain types of cancers.
Out of 14 lakh newly diagnosed cancer patients in India, nearly 2.75 lakh patients are diagnosed with breast, ovarian, prostrate and pancreatic cancers as per Globocan 2022 data. Amongst these patients, those who are diagnosed as HRD positive or with BRACA mutation need to be administered this PARP inhibitor which can delay the progression of the disease. IBYRA is a next gen targeted therapy for HRD positive and BRACA positive cancer patients.
To help identify the right patients and facilitate access, Zydus has collaborated with MedGenome for comprehensive HRD testing. This, alongwith a year-long treatment of IBYRA, has been capped at Rs. 3 lakhs as compared to the cost of around Rs. 72 lakhs by the innovator.
Zydus is one of the leading players in the oncology segment in India. Reportedly, six of its eight oncology pillar brands, Ujvira, Vivitra, Bryxta, Enfiera, Pegstim and Obnyx are leaders in their respective categories.